0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aeolus Pharmaceuticals
Its shares trade under the ticker AOLS. It has been listed since 2 February 1996. In the fiscal year to 30 September 2016, it reported revenue of $2.1m and a net loss of $3.6m. At that date it held total assets of $4.2m and shareholders' equity of $3.2m.
Aeolus Pharmaceuticals, Inc. engages in the development of a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease, and diseases of the central nervous system. The company is headquartered in Mission Viejo, California. The firm focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The firm's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Feb 1996
- Employees
- 4
Leadership
Pay as last reported
- Mr. David CavalierChairman of the Board, Chief Financial Officer, since 2004$374,021
- Mr. John McManusPresident, Chief Executive Officer$497,715
- Mr. John ClericiIndependent Director
- Dr. John FarahIndependent Director
- Mr. Mitchell KayeIndependent Director
- Dr. Amit KumarIndependent Director
- Mr. Chris RallisIndependent Director
- Dr. Jeffrey ScottIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aeolus Pharmaceuticals Inc possesses several strengths that contribute to their competitive advantage. The company has a strong intellectual property portfolio, which includes patents for their innovative drug candidates, providing a significant barrier to entry for competitors. Additionally, Aeolus has a team of highly skilled researchers and scientists who are experts in their respective fields, enabling them to develop novel and effective pharmaceutical products. Furthermore, the company has established strategic partnerships with leading research institutions and biopharmaceutical companies, allowing them to access valuable resources and expertise.
Weaknesses
- Despite its strengths, Aeolus Pharmaceuticals Inc also faces some weaknesses that may hinder its growth and success. One weakness is the company's heavy reliance on external sources of funding to support their research and development efforts. This dependency on funding grants and partnerships can be risky, as it exposes Aeolus to potential fluctuations in funding availability. Additionally, the company's limited market presence and brand recognition compared to larger pharmaceutical companies can make it challenging to gain market share and compete effectively.
Opportunities
- Aeolus Pharmaceuticals Inc has several opportunities in the pharmaceutical industry that can be capitalized on to drive growth and profitability. The increasing demand for innovative and effective treatments for various diseases presents an opportunity for Aeolus to develop and commercialize their drug candidates successfully. Moreover, the growing trend towards personalized medicine and targeted therapies provides Aeolus with the chance to tailor their products to specific patient populations, potentially increasing their market potential. Furthermore, the current regulatory environment, which encourages faster drug approvals and streamlined clinical trials, can enable Aeolus to bring their therapies to market more efficiently.
Threats
- Aeolus Pharmaceuticals Inc must also navigate several threats in the pharmaceutical industry that could impact their business operations. One significant threat is the intense competition from both established pharmaceutical companies and emerging biotechnology firms. These competitors may have larger financial resources and broader product portfolios, posing a challenge to Aeolus's market position. Moreover, the ever-changing regulatory landscape and compliance requirements can increase complexity and costs for drug development and commercialization. Economic factors, such as fluctuating healthcare policies and reimbursement rates, can also impact the pricing and demand for Aeolus's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.